September 16, 2024

Table S1 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics validation cohort, including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU cohort 1.

Me gusta

Guardar

Cite This Study

Yao et al. (Mon,) studied this question.

synapsesocial.com/papers/68e587eeb6db643587523eaf https://doi.org/https://doi.org/10.1158/0008-5472.27027215.v1

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S1 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma2024
2Table S3 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma2024
3Table S3 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma2024
4Table S2 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma2024
5Table S2 from Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma2024

Me gusta

Guardar